NewsEvents

Your Yourlocation: Home > Tiotropium bromide(136310-93-5) production company news

LAMAs have been tested in COPD, with the Boehringer Ingelheim-based product, tiotropium bromide(136310-93-5), with sales of $ 5 billion last year, but LAMA / LABA combination drugs are only available in recent years use.

Novartis is positioning Ultibro as a glucocorticoid-free Sulidide replacement product in line with the Global Initiative for Chronic Obstructive Pulmonary Disease (GOLD) guidelines, which are trying to reduce the long-term use of inhaled steroids. According to the 2014 GOLD guidelines, steroids have been associated with COPD pneumonia and have a slightly increased risk of fracture after prolonged exposure.

This is one of the reasons respiratory experts believe LAMA / LABA will become a new force in the treatment of COPD, including Ultibro, GlaxoSmithKline and Anoro (Umeclidinium bromide) Ringer Ingelheim's tiotropium bromide(136310-93-5) / Olodaterol (under registration), which, Anoro and Ultibro were approved last year.

Decision Resources recently predicted that LAMA / LABA will account for more than one-third of all COPD sales in developed markets by 2020, while Citigroup's analysis predicts sales of these drugs will increase from $ 10 billion this year The dollar grew to $ 14 billion in 2018.

Seretide has faced stiff competition from generics and competitive products from AstraZeneca and Forest Laboratories / Almirall are also being developed, and with the emergence of Cenozoic drugs, the market is expected to become fragmented and difficult to With products such as seretide and tiotropium that have annual sales of billions of dollars.

Novartis also published the results of the QUANTIFY and GLISTEN studies at the European Respiratory Society, a QUANTIFY study showing that the product is superior to tiotropium bromide(136310-93-5) and formoterol, GLISTEN is investigating the addition of glycopyrrolate LABA / inhaled corticosteroid therapy.

Although the data is encouraging compared to its competitors, Novartis is entering a market dominated by its competitors, which in some markets may require additional marketing tools. To achieve this, Novartis signed an agreement with Pfizer to jointly promote Ultibro and Glibenium (Seebri) in the UK.

Address: TEL:0531-82375879 Tiotropium Bromide
© Copyright(C)2014 JINAN DEXINJIA BIO & TECH CO., LTD All Rights Reserved